Learn how to make a generator using DC motors in this step-by-step tutorial. Perfect for DIY enthusiasts and beginners, this ...

Dartmouth-based Voltai, a company that develops motion-powered generators that convert wave and vibration energy into clean electricity, secured the funds after its innovative solution caught the ...

ORLANDO, FLORIDA / ACCESS Newswire / September 26, 2025 / RedChip Companies will air interviews with BioVie Inc. (NASDAQ:BIVI) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks, Big ...

Abstract: The overmodulation (OVM) technique is commonly adopted to fully improve the dc-bus utilization. In this article, a comprehensive investigation of different OVM methods for the dual ...

Abstract: Dual three-phase permanent magnet synchronous generator (DTP-PMSG) offers high efficiency and power density, and is suitable for high-reliability applications. To improve the voltage ...

The update also reduces pricing and adds higher resolution outputs for developers. The update also reduces pricing and adds higher resolution outputs for developers. is a news writer focused on ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking an Ionis-partnered candidate that could offer dosing just once a year into pivotal trials on the strength of ...

The Lions' offense was poor in the 27-13 season-opening loss to the Packers on Sunday. The rebuilt offensive line was a key factor in the unit's underwhelming play. The Lions were kept out of the end ...

Eli Lilly recently announced positive results from its Phase 3 BRUIN CLL-313 trial, revealing significant progression-free survival improvements for its drug Jaypirca in treatment-naive CLL/SLL ...

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug. The ...